

Remarks

Currently Claims 30-37 are pending. Claims 5-6, 14-15 and 19-29 are canceled without prejudice and subject to Applicants' right to file one or more continuation applications directed thereto. Claim 30 is amended to remove "pharmaceutically acceptable derivatives." No new matter is added. Inasmuch as the foregoing amendments place the claims in condition for allowance, or at a minimum narrow the issues for appeal, it is respectfully submitted that entry of the amendment is proper under 37 C.F.R. §1.116. Applicants respectfully request entry of the foregoing amendments.

Section 112, First Paragraph and Section 103(a) Rejections Obviated

Claims 5-6, 14-15 and 19-29 currently stand rejected under 35 U.S.C. §112, first paragraph and Claims 22-24 and 27-29 further stand rejected under 35 U.S.C. §103(a). These rejections are obviated by the instant amendment canceling claims 5-6, 14-15 and 19-29. Withdrawal of these rejections is respectfully requested.

Section 112, Second Paragraph Rejection Overcome

Claims 30-37 currently stand rejected under 35 U.S.C. §112, second paragraph, the Office Action stating that the claims are indefinite for recitation of "pharmaceutically acceptable derivatives" in claim 30. Claim 30 has been amended to remove this recitation. Accordingly, withdrawal of this rejection is respectfully requested.

Applicants respectfully submit that the instant application is in condition for allowance. Inasmuch as the instant Amendment is filed within two (2) months of the mailing date of the final Office Action, prompt issuance of a Notice of Allowance or Advisory Action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case further if desired.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'L. Morgan', with a long horizontal flourish extending to the right.

Lorie Ann Morgan  
Attorney for Applicants  
Registration No. 38,181

Date: 21 July, 2004  
GlaxoSmithKline Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222  
fax: (919) 483-7988  
email: Lorie.A.Morgan@gsk.com